Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
about
Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
P2860
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Surrogate endpoints in metasta ...... e first-line phase III trials.
@en
Surrogate endpoints in metasta ...... e first-line phase III trials.
@nl
type
label
Surrogate endpoints in metasta ...... e first-line phase III trials.
@en
Surrogate endpoints in metasta ...... e first-line phase III trials.
@nl
prefLabel
Surrogate endpoints in metasta ...... e first-line phase III trials.
@en
Surrogate endpoints in metasta ...... e first-line phase III trials.
@nl
P2860
P1433
P1476
Surrogate endpoints in metasta ...... e first-line phase III trials.
@en
P2093
Fausto Petrelli
Sandro Barni
P2860
P2888
P356
10.1007/S12032-013-0776-4
P577
2013-11-23T00:00:00Z